PE20191462A1 - Composicion liquida que contiene pradofloxacina - Google Patents
Composicion liquida que contiene pradofloxacinaInfo
- Publication number
- PE20191462A1 PE20191462A1 PE2019001572A PE2019001572A PE20191462A1 PE 20191462 A1 PE20191462 A1 PE 20191462A1 PE 2019001572 A PE2019001572 A PE 2019001572A PE 2019001572 A PE2019001572 A PE 2019001572A PE 20191462 A1 PE20191462 A1 PE 20191462A1
- Authority
- PE
- Peru
- Prior art keywords
- liquid composition
- composition containing
- pradofloxacin
- containing pradofloxacin
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Fats And Perfumes (AREA)
Abstract
Referido a una composicion liquida que comprende (a) 1 a 30 % (p/v) pradofloxacina, (b) 1 a 30 % (p/v) de un acido; (c) 0.01 a 1 % (p/v) de un antioxidante que se selecciona de acido citrico y tioglicerol; (d) opcionalmente, auxiliares y/o aditivos farmaceuticos aceptables y (e) agua como solvente; dicha solucion tiene un pH de 2 a 5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155885 | 2017-02-13 | ||
| PCT/EP2018/053176 WO2018146194A1 (en) | 2017-02-13 | 2018-02-08 | Liquid composition containing pradofloxacin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191462A1 true PE20191462A1 (es) | 2019-10-16 |
Family
ID=58043920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001572A PE20191462A1 (es) | 2017-02-13 | 2018-02-08 | Composicion liquida que contiene pradofloxacina |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10780168B2 (es) |
| EP (1) | EP3579820B1 (es) |
| JP (1) | JP7257322B2 (es) |
| KR (1) | KR102504435B1 (es) |
| CN (1) | CN110248643B (es) |
| AR (1) | AR111032A1 (es) |
| AU (1) | AU2018217931B2 (es) |
| BR (1) | BR112019016543A2 (es) |
| CA (1) | CA3053211A1 (es) |
| CL (1) | CL2019002283A1 (es) |
| CO (1) | CO2019008677A2 (es) |
| CR (1) | CR20190370A (es) |
| DO (1) | DOP2019000207A (es) |
| ES (1) | ES2886088T3 (es) |
| IL (1) | IL268329B (es) |
| MX (1) | MX2019009572A (es) |
| PE (1) | PE20191462A1 (es) |
| PH (1) | PH12019501946A1 (es) |
| RU (1) | RU2019128568A (es) |
| SG (1) | SG11201907073TA (es) |
| TW (1) | TWI778017B (es) |
| UA (1) | UA124124C2 (es) |
| UY (1) | UY37603A (es) |
| WO (1) | WO2018146194A1 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227918B1 (en) * | 1995-12-21 | 2012-06-28 | Pfizer | Injectable quinolone formulations |
| RU2173318C2 (ru) | 1996-02-23 | 2001-09-10 | Байер Акциенгезелльшафт | 8-циан-1-циклопропил-7-(2,8-диазабицикло(4.3.0)-нонан-8-ил)-6-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновые кислоты, их производные и фармацевтическая композиция, обладающая антибактериальной активностью |
| ID21415A (id) | 1997-12-05 | 1999-06-10 | Upjohn Co | Senyawa-senyawa antibiotik magnesium quinolon |
| DE19854356A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19854357A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19854355A1 (de) | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19908448A1 (de) | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure |
| JP4373649B2 (ja) * | 2002-08-01 | 2009-11-25 | ロート製薬株式会社 | 経口用液剤 |
| DE102004015981A1 (de) | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| EP1757293B1 (en) * | 2004-05-11 | 2012-10-10 | Daiichi Sankyo Company, Limited | Bh4-responsive hyperphenylalaninemia remedies |
| AU2012202013A1 (en) | 2004-12-09 | 2012-05-03 | Bayer Intellectual Property Gmbh | Medicament for hygienic application inside the ear |
| DE102005055385A1 (de) * | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Arzneimittel zur hygienischen Applikation im Ohr |
| JP4921750B2 (ja) * | 2005-09-14 | 2012-04-25 | 株式会社日本点眼薬研究所 | ピレノキシンまたは薬理学的に許容される塩を含有する懸濁性医薬組成物 |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| JP5624281B2 (ja) * | 2009-04-21 | 2014-11-12 | 東亜薬品株式会社 | 光安定性に優れたキノロン系抗菌薬含有液体製剤 |
| CN103830240B (zh) * | 2012-11-27 | 2016-07-06 | 洛阳惠中兽药有限公司 | 一种氟喹诺酮药物组合物 |
| CN102988286A (zh) * | 2012-12-13 | 2013-03-27 | 江苏恒丰强生物技术有限公司 | 一种恩诺沙星注射液 |
| CA2959307C (en) * | 2014-09-04 | 2023-03-28 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| AR105319A1 (es) * | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
-
2018
- 2018-02-08 CN CN201880011402.8A patent/CN110248643B/zh active Active
- 2018-02-08 UA UAA201909560A patent/UA124124C2/uk unknown
- 2018-02-08 SG SG11201907073TA patent/SG11201907073TA/en unknown
- 2018-02-08 CA CA3053211A patent/CA3053211A1/en active Pending
- 2018-02-08 KR KR1020197023567A patent/KR102504435B1/ko active IP Right Grant
- 2018-02-08 JP JP2019543005A patent/JP7257322B2/ja active Active
- 2018-02-08 RU RU2019128568A patent/RU2019128568A/ru unknown
- 2018-02-08 EP EP18702736.2A patent/EP3579820B1/en active Active
- 2018-02-08 ES ES18702736T patent/ES2886088T3/es active Active
- 2018-02-08 AU AU2018217931A patent/AU2018217931B2/en active Active
- 2018-02-08 US US16/484,670 patent/US10780168B2/en active Active
- 2018-02-08 MX MX2019009572A patent/MX2019009572A/es unknown
- 2018-02-08 PE PE2019001572A patent/PE20191462A1/es unknown
- 2018-02-08 BR BR112019016543-6A patent/BR112019016543A2/pt active Search and Examination
- 2018-02-08 CR CR20190370A patent/CR20190370A/es unknown
- 2018-02-08 WO PCT/EP2018/053176 patent/WO2018146194A1/en active Application Filing
- 2018-02-09 AR ARP180100319A patent/AR111032A1/es unknown
- 2018-02-09 UY UY0001037603A patent/UY37603A/es not_active Application Discontinuation
- 2018-02-09 TW TW107104598A patent/TWI778017B/zh active
-
2019
- 2019-07-29 IL IL268329A patent/IL268329B/en unknown
- 2019-08-09 CO CONC2019/0008677A patent/CO2019008677A2/es unknown
- 2019-08-12 CL CL2019002283A patent/CL2019002283A1/es unknown
- 2019-08-13 DO DO2019000207A patent/DOP2019000207A/es unknown
- 2019-08-22 PH PH12019501946A patent/PH12019501946A1/en unknown
-
2020
- 2020-08-20 US US16/998,390 patent/US11617792B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124592T1 (el) | Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| MX2021006035A (es) | Formulaciones cannabinoides estables. | |
| EA201990851A1 (ru) | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201892838A1 (ru) | Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их | |
| EA201892156A1 (ru) | Система доставки | |
| EA201890124A1 (ru) | Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| EA201890592A1 (ru) | Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2 | |
| EA201890247A1 (ru) | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| AR102198A1 (es) | Proceso para reducir partículas subvisibles en una formulación farmacéutica | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| EA202091400A1 (ru) | Производные пиррола в качестве ингибиторов асс | |
| SG10201901426WA (en) | Ophthalmic composition | |
| EA201990093A1 (ru) | Двухкомпонентная композиция | |
| EA201890419A1 (ru) | ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ | |
| PE20191462A1 (es) | Composicion liquida que contiene pradofloxacina | |
| EA201892157A1 (ru) | Фосфаплатиновые жидкие составы | |
| EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| UY37426A (es) | Método para producir una composición farmacéuticamente estable presentada como una solución acuosa | |
| AR103021A1 (es) | Composición antimelanósica para el tratamiento de crustáceos | |
| CY1123214T1 (el) | Συμπλοκα αγομελατινης και σουλφονικα οξεα, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα |